Well-Differentiated Thyroid Gland Carcinoma
NCI Definition: An adenocarcinoma arising from the thyroid gland showing extensive evidence of follicular cell differentiation. According to the nuclear features of the malignant follicular cells, it is classified either as papillary, or follicular carcinoma. 
Well-differentiated thyroid gland carcinomas most frequently harbor alterations in BRAF, NRAS, RET, TP53, and HRAS .
BRAF Mutation, BRAF Exon 15 Mutation, BRAF Codon 600 Missense, BRAF V600E, and NRAS Mutation are the most common alterations in well-differentiated thyroid gland carcinoma .
There are 10 clinical trials for well-differentiated thyroid gland carcinoma, of which 8 are open and 2 are completed or closed. Of the trials that contain well-differentiated thyroid gland carcinoma as an inclusion criterion, 1 is phase 1/phase 2 (1 open), 8 are phase 2 (6 open), and 1 is phase 3 (1 open).
Cabozantinib, lenvatinib, and nivolumab are the most common interventions in well-differentiated thyroid gland carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.